Head-To-Head Contrast: Boston Scientific (BSX) & Invivo Therapeutics (NVIV)
Boston Scientific (NYSE: BSX) and Invivo Therapeutics (NASDAQ:NVIV) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.
This table compares Boston Scientific and Invivo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Boston Scientific and Invivo Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Boston Scientific||$9.05 billion||3.93||$105.00 million||$0.07||370.29|
|Invivo Therapeutics||N/A||N/A||-$23.43 million||($0.85)||-0.56|
Boston Scientific has higher revenue and earnings than Invivo Therapeutics. Invivo Therapeutics is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Boston Scientific has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Boston Scientific and Invivo Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Boston Scientific currently has a consensus price target of $30.87, suggesting a potential upside of 19.08%. Invivo Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 1,150.00%. Given Invivo Therapeutics’ higher probable upside, analysts plainly believe Invivo Therapeutics is more favorable than Boston Scientific.
Insider and Institutional Ownership
90.2% of Boston Scientific shares are owned by institutional investors. Comparatively, 12.0% of Invivo Therapeutics shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by company insiders. Comparatively, 3.9% of Invivo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Boston Scientific beats Invivo Therapeutics on 11 of the 14 factors compared between the two stocks.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.